T2 Biosystems Announces Second Quarter 2023 Financial Results

Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx® Instrument order LEXINGTON,...

Related Keywords

Poland ,John Sperzel ,Gilmartin Group ,Nasdaq ,Vanderbilt University Medical Center ,While The Company ,Resistance Panel ,Globenewswire Inc ,Biosystems Inc ,Company Annual Report On Form ,Exchange Commission ,Bacteria Panel ,Device Designation ,University Medical Center ,Medical Affairs ,Conference Call ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Trip Taylor ,Term Loan ,Markets ,